Ketamine effects on CNS responses assessed with MEG/EEG in a passive auditory sensory-gating paradigm: an attempt for modelling some symptoms of psychosis in man

被引:22
作者
Boeijinga, Peter H.
Soufflet, L.
Santoro, F.
Luthringer, R.
机构
[1] FORENAP, FRP, F-68250 Rouffach, France
[2] FORENAP, FRP, Inst Res Neurosci Neuropharmacol & Psychiat, Rouffach, France
[3] FORENAP Pharma, Rouffach, France
关键词
sensory gating; NMDA receptors; ketamine; human auditory responses; magnetoencephalography; schizophrenia;
D O I
10.1177/0269881107077768
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Disturbances in integrative function have been consistently described in psychotic disorder; for instance, prepulse inhibition of the startle reflex (startle-PPI) which is a marker of sensory gating, is deficient in persons with schizophrenia. The N-methyl-D-aspartate antagonist ketamine produces in control subjects a spectrum of neurobehavioural symptoms like encountered in schizophrenia, and disrupts startLe-PPI in animals. In the present study, we investigated in 12 healthy subjects whether ketamine would reduce sensory-gating in auditory responses at doses which produce psychotic symptoms. in a double-blind, crossover design loading doses of 0.024, 0.081 and 0.27 mg/kg or saline were employed, followed by maintenance infusion for 120 min. A passive paradigm has been developed which consisted in tone bursts, preceded or not by a (near-threshold) click at intervals of 100 ms or 500 ms. Brain electromagnetic activity imaging of the responses to sound stimuli has been carried out by way of a 148-channel magnetoencephatography-system. Actual evoked response amplitudes and underlying equivalent current dipole strengths have been compared to multielectrode evoked potentials from the scalp. A click stimulus is capable to inhibit test responses under placebo at the 100 ms interval. During maintenance infusion of ketamine at steady-state (for >30 min) after 0.27 mg/kg, no such amplitude changes were observed anymore (p < 0.05) and under these circumstances significant increases in Brief Psychiatric Rating scale and Scale for the Assessment of Negative Symptoms scores were evidenced (p < 0.001). Intermediate effects have been observed when the dose was lowered to 0.081 mg/kg. The present results have shown that ketamine may induce a psychotic-like clinical state associated with gating deficits in healthy subjects.
引用
收藏
页码:321 / 337
页数:17
相关论文
共 107 条
[51]   Effect of ketamine on the neuromagnetic mismatch field in healthy humans [J].
Kreitschmann-Andermahr, I ;
Rosburg, T ;
Demme, U ;
Gaser, E ;
Nowak, H ;
Sauer, H .
COGNITIVE BRAIN RESEARCH, 2001, 12 (01) :109-116
[52]   SUBANESTHETIC EFFECTS OF THE NONCOMPETITIVE NMDA ANTAGONIST, KETAMINE, IN HUMANS - PSYCHOTOMIMETIC, PERCEPTUAL, COGNITIVE, AND NEUROENDOCRINE RESPONSES [J].
KRYSTAL, JH ;
KARPER, LP ;
SEIBYL, JP ;
FREEMAN, GK ;
DELANEY, R ;
BREMNER, JD ;
HENINGER, GR ;
BOWERS, MB ;
CHARNEY, DS .
ARCHIVES OF GENERAL PSYCHIATRY, 1994, 51 (03) :199-214
[53]   Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine - Implications for glutamatergic and dopaminergic model psychoses and cognitive function [J].
Krystal, JH ;
Perry, EB ;
Gueorguieva, R ;
Belger, A ;
Madonich, SH ;
Abi-Dargham, A ;
Cooper, TB ;
MacDougall, L ;
Abi-Saab, W ;
D'Souza, DC .
ARCHIVES OF GENERAL PSYCHIATRY, 2005, 62 (09) :985-995
[54]   Therapeutic implications of the hyperglutamatergic effects of NMDA antagonists [J].
Krystal, JH ;
Belger, A ;
D'Souza, DC ;
Anand, A ;
Charney, DS ;
Aghajanian, GK ;
Moghaddam, B .
NEUROPSYCHOPHARMACOLOGY, 1999, 21 (06) :S143-S157
[55]   Effects of ketamine in normal and schizophrenic volunteers [J].
Lahti, AC ;
Weiler, MA ;
Michaelidis, T ;
Parwani, A ;
Tamminga, CA .
NEUROPSYCHOPHARMACOLOGY, 2001, 25 (04) :455-467
[56]  
LeCrubier Y, 1997, ENCEPHALE, V23, P39
[57]   DOPAMINERGIC MECHANISMS IN IDIOPATHIC AND DRUG-INDUCED PSYCHOSES [J].
LIEBERMAN, JA ;
KINON, BJ ;
LOEBEL, AD .
SCHIZOPHRENIA BULLETIN, 1990, 16 (01) :97-110
[58]   Human and animal studies of schizophrenia-related gating deficits. [J].
Light G.A. ;
Braff D.L. .
Current Psychiatry Reports, 1999, 1 (1) :31-40
[59]   Measuring p50 suppression and prepulse inhibition in a single recording session [J].
Light, GA ;
Braff, DL .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (12) :2066-2068
[60]   STUDY OF A NEW SCHIZOPHRENOMIMETIC DRUG - SERNYL [J].
LUBY, ED ;
COHEN, BD ;
ROSENBAUM, G ;
GOTTLIEB, JS ;
KELLEY, R .
ARCHIVES OF NEUROLOGY AND PSYCHIATRY, 1959, 81 (03) :363-369